Single-dose kinetics of primidone in acute viral hepatitis

F. Pisani; E. Perucca; G. Primerano; A. A. D'Agostino; R. M. Petrelli; A. Fazio; G. Oteri; R. Di Perri

doi:10.1007/BF00549596

Single-dose kinetics of primidone in acute viral hepatitis

F. Pisani, E. Perucca, G. Primerano, A. A. D'Agostino, R. M. Petrelli, A. Fazio, G. Oteri, R. Di Perri

Fondazione "Istituto Neurologico Casimiro Mondino"

Research output: Contribution to journal › Article

Abstract

The pharmacokinetics of primidone (PRM) after oral administration of a single 500 mg dose was studied in 7 patients with acute viral hepatitis and 7 healthy control subjects. The elimination half-life and the apparent clearance of unchanged PRM in the patients were 18.0±3.1 h and 42±14 ml·h^-1·kg^-1, respectively (mean ± SD) and did not differ significantly from the values in the controls (half-life 17.0±2.4 h; clearance 35±8 ml·h^-1·kg^-1). The metabolite phenylethylmalonamide (PEMA) was detected in the serum of all normal subjects within 2-24 h. By contrast, serum levels of this metabolite were undetectable (

Original language	English
Pages (from-to)	465-469
Number of pages	5
Journal	European Journal of Clinical Pharmacology
Volume	27
Issue number	4
DOIs	https://doi.org/10.1007/BF00549596
Publication status	Published - Jul 1984

Keywords

primidone
primidone metabolism
single-dose kinetics
viral hepatitis

ASJC Scopus subject areas

Pharmacology, Toxicology and Pharmaceutics(all)
Pharmacology (medical)

Access to Document

10.1007/BF00549596

Fingerprint Dive into the research topics of 'Single-dose kinetics of primidone in acute viral hepatitis'. Together they form a unique fingerprint.

Cite this

Pisani, F., Perucca, E., Primerano, G., D'Agostino, A. A., Petrelli, R. M., Fazio, A., Oteri, G., & Di Perri, R. (1984). Single-dose kinetics of primidone in acute viral hepatitis. European Journal of Clinical Pharmacology, 27(4), 465-469. https://doi.org/10.1007/BF00549596

@article{2ba12a89c26b4a9fbf7f6557a91cfec8,

title = "Single-dose kinetics of primidone in acute viral hepatitis",

abstract = "The pharmacokinetics of primidone (PRM) after oral administration of a single 500 mg dose was studied in 7 patients with acute viral hepatitis and 7 healthy control subjects. The elimination half-life and the apparent clearance of unchanged PRM in the patients were 18.0±3.1 h and 42±14 ml·h-1·kg-1, respectively (mean ± SD) and did not differ significantly from the values in the controls (half-life 17.0±2.4 h; clearance 35±8 ml·h-1·kg-1). The metabolite phenylethylmalonamide (PEMA) was detected in the serum of all normal subjects within 2-24 h. By contrast, serum levels of this metabolite were undetectable (",

keywords = "primidone, primidone metabolism, single-dose kinetics, viral hepatitis",

author = "F. Pisani and E. Perucca and G. Primerano and D'Agostino, {A. A.} and Petrelli, {R. M.} and A. Fazio and G. Oteri and {Di Perri}, R.",

year = "1984",

month = jul,

doi = "10.1007/BF00549596",

language = "English",

volume = "27",

pages = "465--469",

journal = "European Journal of Clinical Pharmacology",

issn = "0031-6970",

publisher = "Springer Verlag",

number = "4",

}

TY - JOUR

T1 - Single-dose kinetics of primidone in acute viral hepatitis

AU - Pisani, F.

AU - Perucca, E.

AU - Primerano, G.

AU - D'Agostino, A. A.

AU - Petrelli, R. M.

AU - Fazio, A.

AU - Oteri, G.

AU - Di Perri, R.

PY - 1984/7

Y1 - 1984/7

N2 - The pharmacokinetics of primidone (PRM) after oral administration of a single 500 mg dose was studied in 7 patients with acute viral hepatitis and 7 healthy control subjects. The elimination half-life and the apparent clearance of unchanged PRM in the patients were 18.0±3.1 h and 42±14 ml·h-1·kg-1, respectively (mean ± SD) and did not differ significantly from the values in the controls (half-life 17.0±2.4 h; clearance 35±8 ml·h-1·kg-1). The metabolite phenylethylmalonamide (PEMA) was detected in the serum of all normal subjects within 2-24 h. By contrast, serum levels of this metabolite were undetectable (

AB - The pharmacokinetics of primidone (PRM) after oral administration of a single 500 mg dose was studied in 7 patients with acute viral hepatitis and 7 healthy control subjects. The elimination half-life and the apparent clearance of unchanged PRM in the patients were 18.0±3.1 h and 42±14 ml·h-1·kg-1, respectively (mean ± SD) and did not differ significantly from the values in the controls (half-life 17.0±2.4 h; clearance 35±8 ml·h-1·kg-1). The metabolite phenylethylmalonamide (PEMA) was detected in the serum of all normal subjects within 2-24 h. By contrast, serum levels of this metabolite were undetectable (

KW - primidone

KW - primidone metabolism

KW - single-dose kinetics

KW - viral hepatitis

UR - http://www.scopus.com/inward/record.url?scp=0021714882&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021714882&partnerID=8YFLogxK

U2 - 10.1007/BF00549596

DO - 10.1007/BF00549596

M3 - Article

C2 - 6519155

AN - SCOPUS:0021714882

VL - 27

SP - 465

EP - 469

JO - European Journal of Clinical Pharmacology

JF - European Journal of Clinical Pharmacology

SN - 0031-6970

IS - 4

ER -